Clinical

Dataset Information

0

METBEIGE Study


ABSTRACT: Interventions: investigational material(s) Generic name etc : Cabozantinib Malate INN of investigational material : Cabozantinib Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material : Cabozantinib: 40 mg or 60 mg, once daily at bedtime, oral, in a 28 day-course. control material(s) Generic name etc : - INN of investigational material : - Therapeutic category code : Dosage and Administration for Investigational material : - Primary outcome(s): safety efficacy - Proportion of subjects with DLT (phase 1 part) - Confirmed ORR by investigators’ assessment in patients who received study treatment as 3rd line or later (phase 2 part) Study Design: An open-label, single arm phase I study and an open-label, randomized controlled multicenter phase II study

DISEASE(S): Colorectal Cancer

PROVIDER: 102460 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

| 98039 | ecrin-mdr-crc
| 97778 | ecrin-mdr-crc
| 97784 | ecrin-mdr-crc
| 102108 | ecrin-mdr-crc
| 100907 | ecrin-mdr-crc
| 102159 | ecrin-mdr-crc
| 98783 | ecrin-mdr-crc
| 99347 | ecrin-mdr-crc
| 99793 | ecrin-mdr-crc
| 100604 | ecrin-mdr-crc